Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8CGO

Structure of human butyrylcholinesterase in complex with N-{[2-(benzyloxy)-3-methoxyphenyl]methyl}-N-[3-(2-fluorophenyl)propyl]cyclobutanamine

Summary for 8CGO
Entry DOI10.2210/pdb8cgo/pdb
DescriptorCholinesterase, alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (10 entities in total)
Functional Keywordsbutyrylcholinesterase, inhibitor, complex., hydrolase
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight63446.12
Authors
Brazzolotto, X.,Pidany, F.,Korabecny, J.,Cahlikova, L.,Nachon, F. (deposition date: 2023-02-06, release date: 2023-06-14, Last modification date: 2024-11-06)
Primary citationPidany, F.,Kroustkova, J.,Al Mamun, A.,Suchankova, D.,Brazzolotto, X.,Nachon, F.,Chantegreil, F.,Dolezal, R.,Pulkrabkova, L.,Muckova, L.,Hrabinova, M.,Finger, V.,Kufa, M.,Soukup, O.,Jun, D.,Jenco, J.,Kunes, J.,Novakova, L.,Korabecny, J.,Cahlikova, L.
Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.
Eur.J.Med.Chem., 252:115301-115301, 2023
Cited by
PubMed Abstract: Butyrylcholinesterase (BChE) is one of the most frequently implicated enzymes in the advanced stage of Alzheimer's disease (AD). As part of our endeavors to develop new drug candidates for AD, we have focused on natural template structures, namely the Amaryllidaceae alkaloids carltonine A and B endowed with high BChE selectivity. Herein, we report the design, synthesis, and in vitro evaluation of 57 novel highly selective human BChE (hBChE) inhibitors. Most synthesized compounds showed hBChE inhibition potency ranging from micromolar to low nanomolar scale. Compounds that revealed BChE inhibition below 100 nM were selected for detailed biological investigation. The CNS-targeted profile of the presented compounds was confirmed theoretically by calculating the BBB score algorithm, these data were corroborated by determining the permeability in vitro using PAMPA-assay for the most active derivatives. The study highlighted compounds 87 (hBChE IC = 3.8 ± 0.2 nM) and 88 (hBChE IC = 5.7 ± 1.5 nM) as the top-ranked BChE inhibitors. Compounds revealed negligible cytotoxicity for the human neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cell lines compared to BChE inhibitory potential. A crystallographic study was performed to inspect the binding mode of compound 87, revealing essential interactions between 87 and hBChE active site. In addition, multidimensional QSAR analyses were applied to determine the relationship between chemical structures and biological activity in a dataset of designed agents. Compound 87 is a promising lead compound with potential implications for treating the late stages of AD.
PubMed: 36996715
DOI: 10.1016/j.ejmech.2023.115301
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.65 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon